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Abstract
Immunosenescence is thought to contribute to the increase of autoimmune
diseases in older people. Immunosenescence is often associated with the
presence of an expanded population of CD4 T cells lacking expression of
CD28 (CD28 ). These highly cytotoxic CD4 T cells were isolated from
disease-affected tissues in patients with rheumatoid arthritis, systemic lupus
erythematosus, multiple sclerosis, or other chronic inflammatory diseases and
their numbers appeared to be linked to disease severity. However, we recently
demonstrated that the common herpes virus, cytomegalovirus (CMV), not
ageing, is the major driver of this subset of cytotoxic T cells. In this review, we
discuss how CMV might potentiate and exacerbate autoimmune disease
through the expansion of CD28  CD4 T cells.
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Autoimmunity is not a rare phenomenon
A degree of autoimmunity that is, reactivity of the immune 
system against our own tissues (‘self’) is found in everybody. 
This is because the immune system’s ability to discriminate 
‘self’ and ‘non-self’ is not perfect. However, this imperfection 
usually is not enough to cause autoimmune disease. It appears 
that autoimmune disease requires “a genetic predisposition and 
environmental factors that trigger the immune pathways that 
lead, ultimately, to tissue destruction”1. This review article was 
prompted by the recent (renewed) interest in CD28null CD4 T 
cell–driven tissue damage and focuses on the adaptive immune 
system. In the following sections, we explore some of these 
factors and a possible environmental trigger for some autoim-
mune diseases. Manifestations of autoimmunity may occur in 
almost any tissue. In someone who has a predisposition to 
autoimmune disease and is exposed to the respective trigger, the 
immune system, however, still has ways of regulating itself in 
order to prevent tissue damage. Some researchers would argue 
that autoimmune disease ultimately results from an imbalance 
between effector and regulatory immune responses (that is, 
between a damaging response and another one keeping it under 
control). This means that immune regulation may still prevent 
the occurrence of autoimmune disease even if an immune 
response against self is present. Disease occurs only if the 
mechanisms preventing tissue damage are no longer sufficient. 
This may happen, for example, if the regulatory response 
for some reason ceases to work or the damaging response is 
boosted.
Predisposition to autoimmune disease
There are many different factors facilitating the develop-
ment of autoimmune disease. Among genetic defects, primary 
immunodeficiencies are often associated with autoimmunity 
and clinical manifestations thereof. Complement deficiencies, 
for example, have long been known to be risk factors for lupus2. 
While infections often are considered the main consequences 
of primary immunodeficiencies, such defects may also interfere 
with immune regulation (for example, in preventing autoreactive 
T cells and B cells from being reined in by regulatory cells). An 
interesting example is a life-threatening autoimmune condition 
known as ‘IPEX syndrome’ (immune dysregulation, polyendo-
crinopathy, enteropathy, X-linked syndrome). It is caused by 
mutations affecting the ‘master regulator’, forkhead box P3 
(FOXP3) gene, an important transcription factor in regulatory 
T cells (Tregs)3. As a result, there is loss of CD4 T-cell regula-
tion, resulting in the production of autoantibodies and tissue 
destruction (the role of Tregs in peripheral tolerance is discussed 
below in the ‘Tolerance versus autoimmunity’ section). An exam-
ple for an acquired predisposition to autoimmune diseases is HIV 
infection. The incidence of rheumatic autoimmune diseases 
observed in HIV infection (which is an acquired immunodefi-
ciency) was relatively low during the era before highly active 
anti-retroviral therapy (HAART). However, following the intro-
duction of HAART, a dramatic increase of conditions linked to an 
increase in CD4 T-cell counts was observed, which underscores 
the important role of CD4 T cells as effectors in such autoimmune 
diseases4,5. A genetic predisposition, importantly, does not have 
to be a defect since many autoimmune diseases are associated 
with major histocompatibility complex (MHC) type. CD4 T cells 
recognise peptide antigens in the context of class II MHC 
molecules, and the mere presence of certain MHC alleles/allele 
groups may predispose an individual to autoimmune disease. 
One explanation for such associations is that MHC molecules 
allow specific, disease-associated peptides to be presented to CD4 
T cells. Such a mechanism, for example, was discovered with 
respect to several HLA-DQB1 (‘DQ2’ and ‘DQ8’) alleles in 
gluten-sensitive enteropathy (‘coeliac disease’). The association 
in this case is so strong that the absence of DQ2 and DQ8 
essentially rules out the disease6. However, it is still only a 
minority of individuals with that tissue type who develop 
autoimmune disease.
Tolerance versus autoimmunity
Tolerance is a state where the immune system tolerates the 
presence of antigens that are recognised by immune cells 
without mounting an attack on the tissues displaying them. 
Whereas passive tolerance (essentially a gap in the immune 
receptor repertoire) is rare and refers to an absence of antigen 
recognition, active tolerance implies that mechanisms oper-
ate that actively down-regulate or suppress an otherwise 
detrimental mechanism. So-called central tolerance (or recessive 
tolerance) is achieved by eliminating all T lymphocytes that 
react with ‘self’ antigens during a rigorous selection process 
in the thymus. T cells bearing T-cell receptors (TCRs) that are 
autoreactive in the context of self-MHC molecules are deleted 
or may be diverted to become Tregs7. However, ‘perfect’ central 
tolerance would require the presence of all relevant self-antigens 
in the thymus in sufficient quantity at the time of TCR selection. 
As this does not seem to be possible, some autoreactive 
cells tend to slip through the selection process8. As a result, 
additional, ‘peripheral’ tolerance mechanisms are required to 
regulate inappropriate activation of autoreactive T cells in the 
periphery. Several different mechanisms contribute to peripheral 
tolerance.
The first important safeguard against the activation of auto-
reactive T cells is the requirement of two signals to induce 
T-cell activation. The interaction of TCRs with MHC/peptide 
complexes on antigen-presenting cells (APCs) (signal 1) alone is 
insufficient to cause T-cell activation. A second, co-stimulatory 
signal is required for full activation. This is usually provided 
by surface ligands called CD80 and CD86 on APCs. These 
interact with the co-stimulatory receptor, CD28, on T cells9–11. 
In the absence of the second signal, T cells become hypo- 
responsive and undergo apoptosis. A second safeguard is 
provided by the expression of the surface receptor molecule, 
cytotoxic T lymphocyte–associated protein 4 (CTLA-4), on 
activated T cells. Its affinity for CD80/CD86 is higher than that 
of CD28 and interaction between the former and CTLA-4 on 
effector T cells dampens down their activity. In addition, CTLA-4 
may remove CD80/86 from APCs. There is strong evidence in 
the literature that regulating CD28-dependent T-cell activation 
is the most important role of CTLA-412. Tregs express CTLA-4 
constitutively and its expression is further stabilised by FOXP3 
expression, a ‘hallmark’ of Tregs. The effect of CTLA-4 liga-
tion on Tregs seems to be an enhancement of suppressor activity. 
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Whether or not the actual signalling through CTLA-4 has any 
role in this process remains controversial. However, suppressor 
activity of Tregs may keep the activation of cytotoxic T cells by 
self-antigens under control13,14.
In some situations, an environmental trigger can breach 
existing tolerance. This can occur by ‘unmasking’ epitopes that 
were not present during selection in the thymus. This is one of 
the postulated mechanisms by which enterovirus infection might 
trigger autoimmune diabetes15. In this review, however, we focus 
on a different virus, cytomegalovirus (CMV), as a possible 
trigger of autoimmune disease. CMV is a common herpes virus. 
The precise mechanisms by which it might trigger autoimmu-
nity have remained obscure but its association with autoimmune 
disease is striking16.
The nature of CD28null T cells
The loss of CD28 associated with cellular senescence is per-
sistent and must not be confused with the short-lived down- 
regulation of CD28 after T-cell activation, which usually reverses 
within 48 hours17. Whereas non-antigen-experienced T cells 
express the co-stimulatory surface receptor, CD28, following 
the encounter of their cognate antigen, antigen-experienced 
T cells proliferate and differentiate along a pathway of increas-
ing maturity that eventually leads to the loss of CD28, at least in 
CD8 T cells. Repeated cell division leads to telomere shorten-
ing down to a critical length below which cells are pushed into 
‘replicative senescence’ and ultimately programmed cell death 
(apoptosis). Cells that have lost part or all of their ability to 
divide are considered senescent. CD28null T cells are ‘terminally 
differentiated’, have shortened telomeres and are often classified 
as senescent. They no longer require CD28 ligation for complete 
activation and at the same time have great cytotoxic potential 
(Table 1). The loss of CD28 expression on both CD4 and CD8 
T cells was long considered to be a consequence of normal 
(immune system) ageing, providing an explanation for accu-
mulations of CD28null T cells in older people18. For example, 
Effros et al. reported that significantly decreased populations 
of CD28+ cells in centenarians compared with younger people 
and a loss of CD28+ T cells in long-term culture appeared 
to indicate that loss of CD28 is a direct consequence of 
immunosenescence19.
Immunosenescence, CD28null CD4 T cells, and 
autoimmunity
Large populations of CD28null CD4 T cells were first identified 
in rheumatoid arthritis (RA) and later found in a wide variety of 
autoimmune diseases ranging from multiple sclerosis (MS) to 
Graves’ disease (GD)20–22. However, the loss of CD28 does not 
seem to indicate ‘anergy’. On the contrary, these cells acquire 
atypical cytotoxic properties resulting in a more rapid response. 
CD28null CD4 T cells have been described to have a memory 
effector phenotype and hence do not require a co-stimulatory 
input to be re-activated23. They are also unusual in having a large 
cytoplasmic store of granzymes and perforins characteristic of 
CD8 T cells and natural killer (NK) cells20. In addition, they 
produce large amounts of pro-inflammatory cytokines such as 
interferon-gamma (IFN-γ) and tumour necrosis factor (TNF), 
which potentially contribute to host tissue damage. Finally, 
CD28null CD4 T cells express NK cell markers such as NKG2D, 
which possibly further contribute to the amplification of the 
pro-inflammatory signals24. These extra receptors also lower the 
threshold for the activation of CD28null CD4 T cells by specific 
and non-specific stimuli25.
Interestingly, CD28null CD4 T cells are resistant to multiple 
forms of regulation. They are resistant to CD4+CD25+Treg- 
mediated suppression, a peripheral tolerance mechanism inhib-
iting proliferation and cytokine production. Tregs were shown 
to be unable to restrict the proliferation of CD28null CD4 T cells 
because of the lack of IL-2 receptor molecules (CD25) on these 
cells26–28. They are also resistant to apoptosis because of the 
down-regulation of the first apoptosis signal Fas receptor 
(Apo-1) and up-regulation of the B-cell lymphoma 2 (Bcl-2) 
apoptosis regulator. Both of these mechanisms contribute 
further to their accumulation29. When CD28null T cells become 
activated, they rapidly express CTLA-4 and generate a pro- 
survival signal by reducing caspase-mediated apoptosis. Anti-
apoptotic resistance is also rendered by B7.1 and B7.2/CTLA-4 
interaction since blocking CTLA-4 increases Fas-FasL-dependent 
apoptosis30. In light of these properties, expansions of CD28null 
CD4 T cells would be expected to be able to drive regulation- 
resistant tissue destruction.
The ‘reversible’ nature of immunosenescence and 
CD28 loss
According to Vallejo et al., persistent loss of CD28 most 
probably depends on repeated or continuous antigen contact17. 
Since CD28 loss on T cells is frequently implicated in the 
development of immunosenescence, it is of interest that others 
have also observed that chronic, persistent antigen stimulation 
(as seen in chronic viral infection or chronic inflammatory/ 
autoimmune disorders) accelerates immunological ageing31,32. 
CMV and HIV infections are prime examples of chronic virus 
infections associated with premature immune senescence33–36 
but hepatitis B virus also appears to be in that category37. These 
observations raise the question as to whether cellular senes-
cence might be reversible if the continuous antigenic stimulation 
were abrogated. And if so, might autoimmunity associated with 
CD28null CD4 T cells be reversible? Warrington et al., back in 
2003, showed that CD28 loss on CD28null CD4 T cells can be 
reversed in vitro by stimulation with IL-1238.
More recently, Akbar et al. reported that cellular senescence 
is an active process that is (at least partly) reversible39. They 
showed that, apart from telomere erosion and DNA damage, a 
nutrient-sensing pathway is also responsible for activating p38 
mitogen-activated protein (MAP) kinase in senescent cells. They 
also showed that small-molecule inhibitors of p38 reconstitute 
proliferation and telomerase activity following T-cell activation39. 
Other studies showed that, in addition to these intrinsic pathways, 
T-cell senescence can be reversed extrinsically by cytokines 
secreted by APCs. A recent study in mice showed that p38 
MAP kinase inhibition in APCs led to an increase in inter-
leukin-12 (IL-12) production, which in turn enhanced T helper 1 
(Th1) responses after vaccination in a mouse model40. It is quite 
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possible that in humans the effect of p38 MAP kinase inhibition 
on cells39 is mediated by IL-12 as well.
The concept that cellular senescence is an active and reversible 
process is very confusing per se, since generally we associate 
the term ‘senescence’ with chronological age (which certainly 
is not reversible). Therefore, it is important to understand that 
senescent cells do not have to be ‘old’ in a chronological sense 
and may occur in young people. The fact that an increase in cells 
with an apparently ‘senescent’ phenotype is often associated 
with older age is explained by the accumulation of antigen- 
experienced cells in older people. Many of these will have been 
exposed to their cognate antigens for a long time and have gone 
through many rounds of proliferation. However, it is important 
to consider that fully functional, terminally differentiated effec-
tor cells would also be expected to produce aggressive cytokines 
(that is, have a secretory phenotype) without necessarily being 
senescent. The CD28null phenotype might include both senescent 
and fully functional effector cells. However, independently 
of these phenotypes, the age of an organism might have an effect 
on cellular function in general. Recent data suggest that, for 
example, naïve T cells in older people already show some signs of 
senescence70.
CD28null CD4 T cells are strongly associated with 
cytomegalovirus infection
Because the prevalence of CMV infection increases with age, it 
was widely believed that CD28null T cells accumulate as a result 
of increasing age71–73. The most conspicuous accumulations of 
CD28null T cells occur in the CD8 compartment. These may be 
found in both young and older people and often constitute 20 
to 80% of CD8 T cells. CD28null CD4 T-cell frequencies are 
generally one if not two orders of magnitude lower than those 
of CD28null CD8 T cells. Interestingly, their frequencies rarely 
exceed 1%, even in very old individuals, unless CMV infection 
is present. Our recent work indeed suggests that CMV infection 
is a major ‘trigger’ for the expansion of CD28null CD4 T cells, 
increasing frequencies more than 10-fold on average. (In CD8 
T cells, the effect was a twofold increase.) However, the mecha-
nisms by which this happens have remained unclear. Our work 
also shows that chronological age has a very small effect on 
CD28null CD4 T-cell expansions and only in CMV+ individuals. 
Likewise, the effect of chronological age on the accumulation of 
CD28null CD8 T cells was found to be quite small. Expansions 
of these cells have long been associated with CMV infection, 
but the strength of the association between large numbers of 
these cells and CMV infection was grossly underestimated. 
Only in the presence of CMV infection do individuals exhibit 
cell numbers typically associated with clinical disease in the lit-
erature (usually several percent)74. A recent publication reported 
that treatment with ganciclovir in CMV+ patients with anti- 
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
reduced the number of CD28null CD4 T cells75. This finding seems 
to support both the ideas that these cells are driven by CMV 
infection and that their effects may be reversible when the 
offending antigen is removed75.
According to our results and those of others, many CD28null CD4 
T cells are CMV-specific; however, it remains unclear whether 
other antigens are also recognised; no published report has ever 
convincingly shown the involvement of non-CMV antigens in 
triggering or driving CD28null CD4 T-cell expansions.
Independently of any association with CMV, increased propor-
tions of CD28null CD4 T cells have been implicated in a wide 
range of autoimmune diseases over more than two decades 
but also in atherosclerosis and coronary heart disease. These 
different ‘strands’ of research appear to have existed independ-
ently of each other35. We recently reviewed the literature on 
these topics and found compelling evidence that CMV is in all 
probability a major driver of vascular complications in RA and 
other chronic inflammatory conditions35,76. However, in exten-
sion of that work, we now explore the role of CD28null CD4 T 
cells in autoimmune and chronic inflammatory diseases more 
generally. Our review brings together studies from different 
areas of autoimmunity all of which suggest a role for CD28null 
CD4 T cells in causing or exacerbating disease77. The presence 
of large numbers of CD28null CD4 T cells in such conditions 
suggests a pathogenic role of this subset and indirectly one of 
CMV infection. Please note that most authors have reported 
increased proportions of these cells in various clinical situations 
rather than increased cell counts per unit of volume of blood 
(‘absolute counts’). Since lymphocytes may be redistributed 
between tissue and blood in different ways depending on a range 
of factors, absolute numbers per unit of blood are not necessar-
ily more useful. In a recent publication, we were able to show 
that CMV-specific CD4 T cells drastically increase at older ages 
in both ‘absolute’ and relative terms; however, it also became 
clear that potentially relevant changes in subset proportions 
may be missed if the size of individual subsets is reported in 
‘absolute’ counts78.
Rheumatoid arthritis
RA is a systemic autoimmune disease and the condition in 
which CD28null CD4 T cells were first described and extensively 
studied21,48,49,79. A positive correlation between the presence of 
CD28null CD4 T cells and the extent of extra-articular manifesta-
tions suggested that these cells mediate some of the systemic 
effects of RA48,80. It is unclear in which compartment these 
cells are originally generated. However, up-regulation of the 
chemokine receptor CX3CR1 on CD28null CD4 T cells might 
allow them to reach the synovial fluid thanks to expression of the 
CX3CR1 ligand, fractalkine (CX3CL1), on synoviocytes81. 
Remarkably, they are rarely found in the synovial membrane 
itself82. Fractalkine and its receptor were previously proposed as 
promising candidates for anti-inflammatory interventions in RA 
but also cardiovascular disease and other chronic inflammatory 
conditions83. In agreement with their role in systemic manifesta-
tions of RA, elevated levels of CD28null CD4 T cells were found, 
for example, in inflammatory pulmonary infiltrates where they 
express increased levels of the α4 integrin (alpha4/beta1, CD11b) 
and CD11a20. Expression of these markers likewise is likely to 
facilitate tissue infiltration. The RA-associated HLA-DRB1*04 
allele group was previously linked to an increase in CD28null 
CD4 T cells in both patients with RA and healthy controls23. 
This might indicate that the presence of HLA-DRB1*04 alleles 
facilitates RA but also an increase in CD28null CD4 T cells. 
Carrying HLA-DRB1*04 in that sense represents a predisposition 
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to autoimmunity; as such, autoimmunity could be mediated at 
least in part by CD28null CD4 T cells recognising a CMV epitope 
in this MHC context; however, to our knowledge, no CMV 
peptide presented by HLA-DRB1*04 has been reported to date. 
Our own work suggests that CMV infection is indeed the trigger 
for the expansions of these T cells.
The antigen specificity of CD28null CD4 T cells is an area of 
great interest, but no antigens apart from CMV have been iden-
tified. Reactivity to CMV antigens was demonstrated in several 
studies, both in patients with RA and in healthy controls20,82,84. 
Interestingly, both CMV DNA- and CMV-specific antibodies 
were reported in the synovial fluid of patients with RA85.
This suggests that CMV might have a direct role in CD28null CD4 
T cell–mediated tissue damage in RA. Based on a number of 
publications, we have devised a hypothetical model how this 
might happen (Figure 1).
We hypothesise that CMV-infected synovial fibroblasts directly 
present CMV antigens to infiltrating T cells in a class II MHC 
context. It has been shown that synovial fibroblasts can activate 
CD28null CD4 T cells. However, the exact antigenic determi-
nants remain unclear50. Synovial fibroblasts might also present 
antigens indirectly via the release of non-infectious exosomes 
(NIEs) containing CMV antigens, as such a mechanism has been 
shown in endothelial cells (ECs). CMV-infected ECs release 
NIEs containing many CMV proteins. Following uptake of these 
NIEs by APCs, the CMV antigens are presented by MHC II 
on APCs to tissue-infiltrating CMV-specific CD4+ T cells86,87. 
Recognition of these antigens by the CD4 T cells would result 
in their activation and production of IFN-γ and TNF, both of 
which may up-regulate fractalkine expression on ECs and 
synoviocytes. This in turn would be likely to attract more 
CX3CR1-expressing CD28null CD4 T cells and Tregs to the 
inflamed synovium. In addition, CMV-specific CD28null CD4 
T cells in the synovium might respond to autoantigens (as a 
result of cross-reactivity) and produce cytotoxic molecules like 
perforins and granzymes. CD28null CD4 T cells might also 
activate macrophages to release IL-1 or TNF or both, which 
could stimulate synovial fibroblasts to cause cartilage erosion 
by promoting connective tissue growth factor88. This is only a 
working model and, though speculative, is supported by the cited 
observations.
Figure 1. Potential link between CD28null T-cells, CMV, and Autoimmunity. (1) Endothelial cells (ECs) and synoviocytes can be 
infected by cytomegalovirus (CMV). (2) Synoviocytes may directly present CMV to CD28null CD4 T cells in the context of class II major 
histocompatibility complex (MHC). (3) Synoviocytes may alternatively release non-infectious exosomes (NIEs) containing the CMV antigens 
(as shown for ECs). Antigen-presenting cells (APCs) will take up the NIEs and process the antigens to be presented on class II MHC. 
(4) APCs present CMV antigens to CMV-specific CD28null CD4 T cells. (5) Activated CD28null CD4 T cells produce interferon-gamma (IFN-γ) 
and tumour necrosis factor (TNF). (6) This in turn will up-regulate the expression of CX3CL1 on synoviocytes and ECs. (7) CX3CR1-
expressing CD28null CD4 T cells (and possibly regulatory T cells [Tregs]) travel from the lymph node to the inflamed joint (via the thoracic 
duct). (8) Interleukin-1 (IL-1) and TNF produced by activated macrophages cause tissue erosion and cartilage destruction. (9) Some 
CMV-specific CD28null CD4 T cells may cross-react with self-antigens. (10) Activated CD28null CD4 T cells evade suppression by Tregs and 
hence maintain an inflammatory state in the rheumatoid arthritis synovium.
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Apart from the adaptive immune response, macrophages and 
synovial fibroblasts might produce chemokines like IL-6, granu-
locyte-macrophage colony-stimulating factor (GM-CSF), and 
TNF in response to the presence of Toll-like receptor (TLR) 
ligands such as proteoglycans and, for example, bacterial DNA 
in the rheumatoid synovium89. TLR-activated dendritic cells 
(DCs) migrate to the local lymph node to differentiate the 
primed autoreactive T cells towards different subtypes such as 
TH1 and TH2 (depending on the released cytokines)90. A role of 
cytokines produced by macrophages and fibroblasts in autoim-
mune disease, in particular the role of TNF, has been well 
established. This is witnessed by the clinical success of anti-TNF 
therapies91. Our model was conceived to illustrate one possi-
ble way how CMV infection might worsen the clinical course of 
RA via CD28null CD4 T cells. We are aware that there may be 
other ways to explain the effect of CMV in autoimmune disease 
and a discussion/exploration of all these possibilities is urgently 
needed.
Multiple sclerosis
MS is a debilitating autoimmune disease characterised by 
demyelination and axonal loss92. Myelin-specific T cells have been 
shown to be associated with the neuronal damage in patients with 
MS. In addition, genetic predisposition and other environmen-
tal factors have been identified as contributors. There is a strong 
association of MS with the HLA-DR15 and HLA DQ6 alleles. 
Among the environmental triggers, vitamin D deficiency and 
Epstein–Barr virus have long been associated with the disease93. 
Both CD4+ and CD8+ T cells have been proposed to play a role in 
disease progression.
Cytotoxic CD28null CD4 T cells are indeed found in increased 
proportions in patients with MS. They display up-regulated cell 
adhesion molecules, which probably allow them to infiltrate 
the brain and destroy oligodendrocytes34,41,94,95. Thewissen et al. 
reported that CD28null CD4 T-cell reactivity against myelin basic 
protein (MBP) in patients with MS was limited20. However, in 
another study, cross-reactivity between a myelin peptide (MOG 
35-55) and a CMV antigen UL-86 (981-1003) was observed in 
both rats and non-human primates42.
In a recent publication, CMV seropositivity of patients with 
MS was associated with higher percentages of CD28null CD4 
T cells34. Although no direct evidence of an association of 
CD28null CD4 T cells with MS severity was found in humans, 
the authors observed expansion of CD28null CD4 T cells in 
response to CMV infection in a mouse CMV (MCMV) model. 
There was a direct correlation between the frequencies of 
CD28null CD4 T cells and disease severity in a mouse model 
of MS, referred to as experimental autoimmune encephalitis 
(EAE)34. Infection of EAE mice with MCMV further increased 
the frequencies of CD28null CD4 T cells. In these mouse 
models, CD28null CD4 T cells could also be induced by repeated 
stimulation of T cells with MBP or tetanus toxoid in vitro, 
indicating that the CD28null phenotype of CD4 T cells is not 
strictly antigen-dependent in these animals. Antigens other than 
CMV inducing this phenotype in humans, however, have not 
yet been identified. It is of note that CMV-specific CD8 T cells 
were previously reported in MS lesions96.
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) affects multiple organs 
and is associated with increased mortality and morbidity. Most 
patients with SLE have sera positive for autoantibodies against 
La protein, which is a small ribonucleoprotein (RNP) associated 
with RNA polymerase. Interestingly, many viruses use La 
protein for their replication. A recent review on CMV infection 
in childhood-onset SLE describes CMV to either be the trigger 
of the disease or be responsible for a flare. This hypothesis is 
based on the association of La autoantibodies and latent CMV 
infection in many patients97. Another study identified antibodies 
against the 47-kD La protein (SS-B) that recognised epitopes 
exhibiting sequence similarity with many herpes viruses, 
including CMV98. Recently, the role of T cells in SLE has been 
recognised; T cells in SLE were shown to have a lower threshold 
for activation. Different mechanisms by which these T cells lower 
their activation threshold were discussed in a recent review 
by Mak and Kow99. T cells in patients with SLE were shown to 
have decreased levels of CD3 ζ-chain (zeta chain) expression, 
measured by anti-CD3-ζ immunoblots, as compared with healthy 
controls. These so-called ‘lupus T cells’ were predominantly 
CD8+ and CD16+100. Decreased levels of CD3 ζ-chain expres-
sion leads to a rewiring of the downstream ZaP-70 signalling 
pathway. This causes an increased calcium flux and greater 
activation of these T cells99. Further work is required to 
characterise these T cells with regard to other co-stimulatory 
molecules, especially CD28, in the context of CMV infection. 
Also, it would be interesting to assess the potential cross-reactivity 
of CMV-reactive T cells with La protein.
Graves’ disease
GD is an autoimmune disease that affects the thyroid glands. 
Anti-thyrotropin-stimulating receptor antibodies were found 
to cause goitre and hyperthyroidism in these patients. A recent 
study found increased levels of CD28null CD4 T cells in GD patients 
compared with healthy controls. The same study found that the 
numbers of CD28null CD4 T cells correlated with the severity of 
the goitre and the ophthalmopathy. In patients with goitre-like 
symptoms, 15% of the total lymphocytes were CD28null CD4 
T cells compared with only 6% in patients without goitre-
like symptoms22. Giving further support to a role of these 
T cells, the percentages of IFN-γ-producing CD28null CD4 T cells 
correlated with those of anti-thyrotropin-stimulating receptor 
autoantibodies (r = 0.4581, P = 0.002).
IFN-γ-producing CD28null CD4 T cells were found not only in 
the circulation but also, in high numbers, in affected tissues such 
as the muscles in the eye and the thyroid59,101. High levels of 
circulating IFN-γ were observed in patients with GD and this 
might drive the destruction of thyroid tissue22,60.
The role of virus infections in GD has been addressed in 
previous studies. For example, antibodies against the capsid 
antigens of Epstein–Barr virus were found at higher titers102. 
However, the sera of these patients were not examined for anti- 
CMV antibodies. Since CMV is the driver of the CD28null CD4 
T-cell population, a possible role for CMV in GD should be 
investigated.
Page 8 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
Therapies targeting CD28null CD4 T cells
The consistent presence of potentially highly pathogenic 
CD28null CD4 T cells across different autoimmune diseases 
potentially makes them an interesting target for immunotherapy, 
and some immunotherapies that are currently in clinical use 
were shown to have effects on this subset, such as reducing its 
frequency or reversing its phenotype by causing re-expression of 
CD28. For example, anti-TNF-α therapy, which is widely used 
in the treatment of RA, was shown to limit the expansion and 
cytotoxic effects of CD28null CD4 T cells32. Discontinuation of 
anti-TNF conversely may increase the risk of disease flares103. 
Methotrexate leads to a reduction of CD28null CD4 T-cell 
levels, whereas infliximab induces the re-expression of 
CD2851. Others have shown re-expression of CD28 by IL-12 
stimulation38. However, it remains unclear at this time what 
effect, for example, re-expression of CD28 might have.
CD28null CD4 T cells are generally considered senescent cells as 
they have lost the ability to proliferate. Senescent cells usually 
have shortened telomeres, which activate the DNA damage repair 
(DDR) pathway. This pathway allows cells to be eliminated 
before they can pose a threat to the organism. (The mechanisms 
of senescence and exhaustion of T cells were reviewed in great 
detail in a recent review104.) However, it appears that therapies 
aiming to reverse the senescence of CD28null CD4 T cells could 
be helpful for improving vaccination results. On the other 
hand, this might carry the risk of generating malignant cells. In 
addition, we believe it cannot be fully excluded that re-activat-
ing senescent CD28null CD4 T cells could worsen some of the 
conditions associated with their expansion. This could be the 
result of allowing even further proliferation of the then ‘reverted’ 
cells which now would be expressing CD28. (This is implying 
that in some situations senescent CD28null T cells could do less 
harm than their CD28+ counterparts.)
Therefore, therapies removing CD28null CD4 T cells might 
be a safer option and more beneficial. In theory, this could be 
achieved by targeting specific molecules on the CD28null CD4 
T subset or by inducing apoptosis specifically of this subset. For 
example, apoptosis of CD28null CD4 T cells has been achieved 
by using the lipid-lowering rosuvastatin in patients with coro-
nary heart disease105. To reduce the tissue-infiltrating capacity of 
CD28null CD4 T cells, Broux et al. have suggested blocking 
CX3CR1 on these cells41. It will be important for the success of 
any of these therapies to characterise CD28null CD4 T cells in 
more detail and to identify both their antigenic specificity and 
molecular markers. Additionally, antiviral therapies such as 
ganciclovir could potentially help to reduce the expansion of the 
CD28null CD4 T cells and hence possibly reduce the severity of 
many of the autoimmune diseases. However, the way in which 
such a strategy might be used clinically is, in reality, far from 
clear.
Conclusion and future perspective
CD28null CD4 T cells are an unusual population of chronically 
stimulated cells. In humans, they appear to accumulate in the 
presence of CMV infection. They are cytotoxic, produce large 
quantities of cytokines (a secretory phenotype associated with 
senescence) and display increased levels of adhesion markers, 
which suggests that they have access to diverse tissues. Their 
mere presence in autoimmune disease does not prove that they 
are actually involved in it or even cause it. However, reports 
indicating a correlation of their frequencies with severity suggest 
direct involvement in causing pathology. Studies in which these 
cells are specifically targeted might show to what extent they 
are involved in disease progression. Understanding the different 
antigenic specificities of these cells is a major challenge but will 
be helpful for developing specific immunotherapies. CMV is the 
clear trigger for the accumulation of these cells. However, we 
still do not know exactly which antigens (apart from CMV) these 
cells recognise. A better understanding of the antigen specificity 
of CD28null CD4 T cells would be a big step forward.
Grant information
The author(s) declared that no grants were involved in supporting 
this work. 
Acknowledgements
We would like to thank Joyce Bowden for her contribution.
References F1000 recommended
1.  Wang L, Wang FS, Gershwin ME: Human autoimmune diseases: a 
comprehensive update. J Intern Med. 2015; 278(4): 369–95.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
2. Sullivan KE: Complement deficiency and autoimmunity. Curr Opin Pediatr. 1998; 
10(6): 600–6.  
PubMed Abstract | Publisher Full Text 
3. Wildin RS, Ramsdell F, Peake J, et al.: X-linked neonatal diabetes mellitus, 
enteropathy and endocrinopathy syndrome is the human equivalent of mouse 
scurfy. Nat Genet. 2001; 27(1): 18–20.  
PubMed Abstract | Publisher Full Text 
4. Calabrese LH, Kirchner E, Shrestha R: Rheumatic complications of human 
immunodeficiency virus infection in the era of highly active antiretroviral 
therapy: emergence of a new syndrome of immune reconstitution and 
changing patterns of disease. Semin Arthritis Rheum. 2005; 35(3): 166–74. 
PubMed Abstract | Publisher Full Text 
5.  Yang JJ, Tsai MS, Sun HY, et al.: Autoimmune diseases-related arthritis in 
HIV-infected patients in the era of highly active antiretroviral therapy.  
J Microbiol Immunol Infect. 2015; 48(2): 130–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
6. Kagnoff MF: Celiac disease: pathogenesis of a model immunogenetic disease. 
J Clin Invest. 2007; 117(1): 41–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Xing Y, Hogquist KA: T-cell tolerance: central and peripheral. Cold Spring Harb 
Perspect Biol. 2012; 4(6): pii: a006957.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. von Boehmer H: Central tolerance: essential for preventing autoimmune 
Page 9 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
disease? Eur J Immunol. 2009; 39(9): 2313–6.  
PubMed Abstract | Publisher Full Text 
9. Smith-Garvin JE, Koretzky GA, Jordan MS: T cell activation. Annu Rev Immunol. 
2009; 27: 591–619.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Lafferty KJ, Cunningham AJ: A new analysis of allogeneic interactions. Aust J 
Exp Biol Med Sci. 1975; 53(1): 27–42.  
PubMed Abstract | Publisher Full Text 
11. Holtzman MJ, Green JM, Jayaraman S, et al.: Regulation of T cell apoptosis. 
Apoptosis. 2000; 5(5): 459–71.  
PubMed Abstract | Publisher Full Text 
12. Walker LS: Treg and CTLA-4: two intertwining pathways to immune tolerance.  
J Autoimmun. 2013; 45: 49–57.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Jain N, Nguyen H, Chambers C, et al.: Dual function of CTLA-4 in regulatory 
T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl 
Acad Sci U S A. 2010; 107(4): 1524–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
14. Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al.: Intrinsic and extrinsic 
control of peripheral T-cell tolerance by costimulatory molecules of the 
CD28/ B7 family. Immunol Rev. 2011; 241(1): 180–205.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15.  Honkanen H, Oikarinen S, Nurminen N, et al.: Detection of enteroviruses in 
stools precedes islet autoimmunity by several months: possible evidence for 
slowly operating mechanisms in virus-induced autoimmunity. Diabetologia. 
2017; 60(3): 424–31.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
16.  Halenius A, Hengel H: Human cytomegalovirus and autoimmune disease. 
Biomed Res Int. 2014; 2014: 472978.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
17. Vallejo AN, Brandes JC, Weyand CM, et al.: Modulation of CD28 expression: 
distinct regulatory pathways during activation and replicative senescence.  
J Immunol. 1999; 162(11): 6572–9.  
PubMed Abstract 
18. Weng NP, Akbar AN, Goronzy J: CD28- T cells: their role in the age-associated 
decline of immune function. Trends Immunol. 2009; 30(7): 306–12.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Effros RB, Boucher N, Porter V, et al.: Decline in CD28+ T cells in centenarians 
and in long-term T cell cultures: a possible cause for both in vivo and in vitro 
immunosenescence. Exp Gerontol. 1994; 29(6): 601–9.  
PubMed Abstract | Publisher Full Text 
20. Thewissen M, Somers V, Hellings N, et al.: CD4+CD28null T cells in 
autoimmune disease: pathogenic features and decreased susceptibility to 
immunoregulation. J Immunol. 2007; 179(10): 6514–23.  
PubMed Abstract | Publisher Full Text 
21. Schmidt D, Goronzy JJ, Weyand CM: CD4+ CD7- CD28- T cells are expanded in 
rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest. 1996; 
97(9): 2027–37.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Sun Z, Zhong W, Lu X, et al.: Association of Graves’ disease and prevalence of 
circulating IFN-gamma-producing CD28- T cells. J Clin Immunol. 2008; 28(5): 
464–72.  
PubMed Abstract | Publisher Full Text 
23. Thewissen M, Somers V, Venken K, et al.: Analyses of immunosenescent 
markers in patients with autoimmune disease. Clin Immunol. 2007; 123(2): 
209–18.  
PubMed Abstract | Publisher Full Text 
24. Warrington KJ, Takemura S, Goronzy JJ, et al.: CD4+,CD28- T cells in rheumatoid 
arthritis patients combine features of the innate and adaptive immune 
systems. Arthritis Rheum. 2001; 44(1): 13–20.  
PubMed Abstract | Publisher Full Text 
25. Lindstrom TM, Robinson WH: Rheumatoid arthritis: a role for immunosenescence? 
J Am Geriatr Soc. 2010; 58(8): 1565–75.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Shevach EM: CD4+ CD25+ suppressor T cells: more questions than answers. 
Nat Rev Immunol. 2002; 2(6): 389–400.  
PubMed Abstract | Publisher Full Text 
27.  Appay V, Zaunders JJ, Papagno L, et al.: Characterization of CD4+ CTLs ex 
vivo. J Immunol. 2002; 168(11): 5954–8.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
28. Vallejo AN, Schirmer M, Weyand CM, et al.: Clonality and longevity of 
CD4+CD28null T cells are associated with defects in apoptotic pathways.  
J Immunol. 2000; 165(11): 6301–7.  
PubMed Abstract | Publisher Full Text 
29.  Markovic-Plese S, Cortese I, Wandinger KP, et al.: CD4+CD28- costimulation-
independent T cells in multiple sclerosis. J Clin Invest. 2001; 108(8): 1185–94. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
30.  Hoff H, Knieke K, Cabail Z, et al.: Surface CD152 (CTLA-4) expression and 
signaling dictates longevity of CD28null T cells. J Immunol. 2009; 182(9): 5342–51. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
31.  Dumitriu IE: The life (and death) of CD4+ CD28null T cells in inflammatory 
diseases. Immunology. 2015; 146(2): 185–93.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
32. Lee GH, Lee WW: Unusual CD4+CD28- T Cells and Their Pathogenic Role in 
Chronic Inflammatory Disorders. Immune Netw. 2016; 16(6): 322–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
33. Fernandez S, French MA, Price P: Immunosenescent CD57+CD4+ T-cells 
accumulate and contribute to interferon-γ responses in HIV patients 
responding stably to ART. Dis Markers. 2011; 31(6): 337–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34.  Vanheusden M, Broux B, Welten SPM, et al.: Cytomegalovirus infection 
exacerbates autoimmune mediated neuroinflammation. Sci Rep. 2017; 7(1): 
663.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
35. Broadley I, Pera A, Morrow G, et al.: Expansions of Cytotoxic CD4+CD28- T Cells 
Drive Excess Cardiovascular Mortality in Rheumatoid Arthritis and Other 
Chronic Inflammatory Conditions and Are Triggered by CMV Infection. Front 
Immunol. 2017; 8: 195.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36.  Slot MC, Kroon AA, Damoiseaux JGMC, et al.: CD4+CD28null T Cells 
are related to previous cytomegalovirus infection but not to accelerated 
atherosclerosis in ANCA-associated vasculitis. Rheumatol Int. 2017; 37(5): 
791–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
37. Wang Y, Bai J, Li F, et al.: Characteristics of expanded CD4+CD28null T cells in 
patients with chronic hepatitis B. Immunol Invest. 2009; 38(5): 434–46.  
PubMed Abstract | Publisher Full Text 
38. Warrington KJ, Vallejo AN, Weyand CM, et al.: CD28 loss in senescent CD4+ 
T cells: Reversal by interleukin-12 stimulation. Blood. 2003; 101(9): 3543–9. 
PubMed Abstract | Publisher Full Text 
39.  Akbar AN, Henson SM, Lanna A: Senescence of T Lymphocytes: 
Implications for Enhancing Human Immunity. Trends Immunol. 2016; 37(12): 
866–76.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
40. Yang Z, Zhang X, Darrah PA, et al.: The regulation of Th1 responses by the p38 
MAPK. J Immunol. 2010; 185(10): 6205–13.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Broux B, Pannemans K, Zhang X, et al.: CX3CR1 drives cytotoxic CD4+CD28- T 
cells into the brain of multiple sclerosis patients. J Autoimmun. 2012; 38(1): 
10–9.  
PubMed Abstract | Publisher Full Text
42. Brok HP, Boven L, van Meurs M, et al.: The human CMV-UL86 peptide 981-1003 
shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 
34-56, but lacks the capacity to induce EAE in rhesus monkeys.  
J Neuroimmunol. 2007; 182(1–2): 135–52.  
PubMed Abstract | Publisher Full Text
43. Miyazaki Y, Iwabuchi K, Kikuchi S, et al.: Expansion of CD4+CD28- T cells 
producing high levels of interferon-{gamma} in peripheral blood of patients 
with multiple sclerosis. Mult Scler. 2008; 14(8): 1044–55.  
PubMed Abstract | Publisher Full Text 
44.  Broux B, Mizee MR, Vanheusden M, et al.: IL-15 amplifies the pathogenic 
properties of CD4+CD28- T cells in multiple sclerosis. J Immunol. 2015; 194(5): 
2099–109.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
45.  Peeters LM, Vanheusden M, Somers V, et al.: Cytotoxic CD4+ T Cells Drive 
Multiple Sclerosis Progression. Front Immunol. 2017; 8: 1160.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
46.  Zheng MM, Zhang XH: Cross-reactivity between human cytomegalovirus 
peptide 981-1003 and myelin oligodendroglia glycoprotein peptide 35-55 in 
experimental autoimmune encephalomyelitis in Lewis rats. Biochem Biophys 
Res Commun. 2014; 443(3): 1118–23.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
47. Tejada-Simon MV, Zang YC, Hong J, et al.: Cross-reactivity with myelin basic 
protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003; 53(2): 
189–97.  
PubMed Abstract | Publisher Full Text
48. Martens PB, Goronzy JJ, Schaid D, et al.: Expansion of unusual CD4+ T cells in 
severe rheumatoid arthritis. Arthritis Rheum. 1997; 40(6): 1106–14.  
PubMed Abstract | Publisher Full Text 
49. Namekawa T, Wagner UG, Goronzy JJ, et al.: Functional subsets of CD4 T cells 
in rheumatoid synovitis. Arthritis Rheum. 1998; 41(12): 2108–16.  
PubMed Abstract | Publisher Full Text
50. Sawai H, Park YW, He X, et al.: Fractalkine mediates T cell-dependent 
proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 
2007; 56(10): 3215–25.  
PubMed Abstract | Publisher Full Text
51. Maly K, Schirmer M: The story of CD4+ CD28- T cells revisited: solved or still 
ongoing? J Immunol Res. 2015; 2015: 348746.  
PubMed Abstract | Publisher Full Text | Free Full Text
52. Sawai H, Park YW, Roberson J, et al.: T cell costimulation by fractalkine-expressing 
synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2005; 52(5): 1392–401.  
PubMed Abstract | Publisher Full Text
Page 10 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
53. Fasth AER, Björkström NK, Anthoni M, et al.: Activating NK-cell receptors 
co-stimulate CD4+CD28- T cells in patients with rheumatoid arthritis. Eur J 
Immunol. 2010; 40(2): 378–87.  
PubMed Abstract | Publisher Full Text 
54. Berg L, Rönnelid J, Sanjeevi CB, et al.: Interferon-gamma production in 
response to in vitro stimulation with collagen type II in rheumatoid arthritis is 
associated with HLA-DRB1*0401 and HLA-DQ8. Arthritis Res. 2000; 2(1): 75–84. 
PubMed Abstract | Publisher Full Text | Free Full Text 
55. Zhang X, Nakajima T, Goronzy JJ, et al.: Tissue trafficking patterns of effector 
memory CD4+ T cells in rheumatoid arthritis. Arthritis Rheum. 2005; 52(12): 
3839–49.  
PubMed Abstract | Publisher Full Text 
56. Turesson C, Matteson EL, Colby TV, et al.: Increased CD4+ T cell infiltrates 
in rheumatoid arthritis-associated interstitial pneumonitis compared with 
idiopathic interstitial pneumonitis. Arthritis Rheum. 2005; 52(1): 73–9.  
PubMed Abstract | Publisher Full Text 
57. Gerli R, Schillaci G, Giordano A, et al.: CD4+CD28- T lymphocytes contribute to 
early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004; 
109(22): 2744–8.  
PubMed Abstract | Publisher Full Text 
58. Pawlik A, Ostanek L, Brzosko I, et al.: Therapy with infliximab decreases 
the CD4+CD28- T cell compartment in peripheral blood in patients with 
rheumatoid arthritis. Rheumatol Int. 2004; 24(6): 351–4.  
PubMed Abstract | Publisher Full Text
59. Hiromatsu Y, Yang D, Bednarczuk T, et al.: Cytokine profiles in eye muscle 
tissue and orbital fat tissue from patients with thyroid-associated 
ophthalmopathy. J Clin Endocrinol Metab. 2000; 85(3): 1194–9.  
PubMed Abstract | Publisher Full Text
60.  Wang F, Chen L, Shen Q, et al.: Characterization and clinical relevance of 
circulating CD4+CD28- T cells in Graves’ disease. Immunol Lett. 2015; 165(1): 
47–51.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation
61. Yang D, Wang H, Ni B, et al.: Mutual activation of CD4+ T cells and monocytes 
mediated by NKG2D-MIC interaction requires IFN-gamma production in 
systemic lupus erythematosus. Mol Immunol. 2009; 46(7): 1432–42.  
PubMed Abstract | Publisher Full Text 
62. Kita Y, Kuroda K, Mimori T, et al.: T cell receptor clonotypes in skin lesions from 
patients with systemic lupus erythematosus. J Invest Dermatol. 1998; 110(1): 41–6.  
PubMed Abstract | Publisher Full Text 
63.  Piantoni S, Regola F, Zanola A, et al.: Effector T-cells are expanded in 
systemic lupus erythematosus patients with high disease activity and damage 
indexes. Lupus. 2018; 27(1): 143–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
64.  Ugarte-Gil MF, Sánchez-Zúñiga C, Gamboa-Cárdenas RV, et al.: 
Circulating CD4+CD28null and extra-thymic CD4+CD8+ double positive T 
cells are independently associated with disease damage in systemic lupus 
erythematosus patients. Lupus. 2016; 25(3): 233–40.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
65. Francis L, Perl A: Infection in systemic lupus erythematosus: friend or foe? Int 
J Clin Rheumtol. 2010; 5(1): 59–74.  
PubMed Abstract | Free Full Text 
66. Hsieh AH, Jhou YJ, Liang CT, et al.: Fragment of tegument protein pp65 of 
human cytomegalovirus induces autoantibodies in BALB/c mice. Arthritis Res 
Ther. 2011; 13(5): R162.  
PubMed Abstract | Publisher Full Text | Free Full Text 
67. Bason C, Corrocher R, Lunardi C, et al.: Interaction of antibodies against 
cytomegalovirus with heat-shock protein 60 in pathogenesis of 
atherosclerosis. Lancet. 2003; 362(9400): 1971–7.  
PubMed Abstract | Publisher Full Text 
68. Brugaletta S, Biasucci LM, Pinnelli M, et al.: Novel anti-inflammatory effect of 
statins: reduction of CD4+CD28null T lymphocyte frequency in patients with 
unstable angina. Heart. 2006; 92(2): 249–50.  
PubMed Abstract | Publisher Full Text | Free Full Text 
69. Zal B, Kaski JC, Arno G, et al.: Heat-shock protein 60-reactive CD4+CD28null  
T cells in patients with acute coronary syndromes. Circulation. 2004; 109(10): 
1230–5.  
PubMed Abstract | Publisher Full Text
70.  Goronzy JJ, Fang F, Cavanagh MM, et al.: Naive T cell maintenance and 
function in human aging. J Immunol. 2015; 194(9): 4073–80.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
71. Weinberger B, Lazuardi L, Weiskirchner I, et al.: Healthy aging and latent 
infection with CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in 
the elderly. Hum Immunol. 2007; 68(2): 86–90.  
PubMed Abstract | Publisher Full Text 
72.  Weltevrede M, Eilers R, de Melker HE, et al.: Cytomegalovirus persistence 
and T-cell immunosenescence in people aged fifty and older: A systematic 
review. Exp Gerontol. 2016; 77: 87–95.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
73. Olsson J, Wikby A, Johansson B, et al.: Age-related change in peripheral blood T-
lymphocyte subpopulations and cytomegalovirus infection in the very old: the 
Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000; 121(1–3): 
187–201.  
PubMed Abstract | Publisher Full Text 
74. Pera A, Caserta S, Albanese F, et al.: CD28null pro-atherogenic CD4 T-
cells explain the link between CMV infection and an increased risk of 
cardiovascular death. Theranostics. 2018; 8(16): 4509–19.  
PubMed Abstract | Publisher Full Text | Free Full Text 
75.  Chanouzas D, Sagmeister M, Faustini S, et al.: Subclinical Reactivation of 
Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune 
Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic 
Antibody-Associated Vasculitis. J Infect Dis. 2019; 219(2): 234–44.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
76. Pera A, Broadley I, Davies KA, et al.: Cytomegalovirus as a Driver of Excess 
Cardiovascular Mortality in Rheumatoid Arthritis: A Red Herring or a Smoking 
Gun? Circ Res. 2017; 120(2): 274–7.  
PubMed Abstract | Publisher Full Text 
77. Thewissen M, Linsen L, Somers V, et al.: Premature immunosenescence in 
rheumatoid arthritis and multiple sclerosis patients. Ann N Y Acad Sci. 2005; 
1051: 255–62.  
PubMed Abstract | Publisher Full Text 
78. Bajwa M, Vita S, Vescovini R, et al.: CMV-Specific T-cell Responses at Older 
Ages: Broad Responses With a Large Central Memory Component May Be Key 
to Long-term Survival. J Infect Dis. 2017; 215(18): 1212–20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
79. Fasth AER, Cao D, van Vollenhoven R, et al.: CD28nullCD4+ T cells--
characterization of an effector memory T-cell population in patients with 
rheumatoid arthritis. Scand J Immunol. 2004; 60(1–2): 199–208.  
PubMed Abstract | Publisher Full Text 
80. Pawlik A, Ostanek L, Brzosko I, et al.: The expansion of CD4+CD28- T cells 
in patients with rheumatoid arthritis. Arthritis Res Ther. 2003; 5(4): R210–3. 
PubMed Abstract | Publisher Full Text | Free Full Text 
81. Goronzy JJ, Henel G, Sawai H, et al.: Costimulatory pathways in rheumatoid 
synovitis and T-cell senescence. Ann N Y Acad Sci. 2005; 1062: 182–94.  
PubMed Abstract | Publisher Full Text 
82. Fasth AE, Snir O, Johansson AA, et al.: Skewed distribution of proinflammatory 
CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther. 2007; 9(5): R87. 
PubMed Abstract | Publisher Full Text | Free Full Text 
83. Jones B, Koch AE, Ahmed S: Pathological role of fractalkine/CX3CL1 in 
rheumatic diseases: a unique chemokine with multiple functions. Front 
Immunol. 2011; 2: 82.  
PubMed Abstract | Publisher Full Text | Free Full Text 
84.  van Leeuwen EM, Remmerswaal EB, Vossen MT, et al.: Emergence of a 
CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery 
of primary cytomegalovirus infection. J Immunol. 2004; 173(3): 1834–41.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
85. Einsele H, Steidle M, Müller CA, et al.: Demonstration of cytomegalovirus (CMV) 
DNA and anti-CMV response in the synovial membrane and serum of patients 
with rheumatoid arthritis. J Rheumatol. 1992; 19(5): 677–81.  
PubMed Abstract 
86. Mehraein Y, Lennerz C, Ehlhardt S, et al.: Latent Epstein-Barr virus (EBV) 
infection and cytomegalovirus (CMV) infection in synovial tissue of 
autoimmune chronic arthritis determined by RNA- and DNA-in situ 
hybridization. Mod Pathol. 2004; 17(7): 781–9.  
PubMed Abstract | Publisher Full Text 
87. Walker JD, Maier CL, Pober JS: Cytomegalovirus-infected human endothelial 
cells can stimulate allogeneic CD4+ memory T cells by releasing antigenic 
exosomes. J Immunol. 2009; 182(3): 1548–59.  
PubMed Abstract | Publisher Full Text | Free Full Text 
88. Nozawa K, Fujishiro M, Takasaki Y, et al.: Inhibition of rheumatoid arthritis by 
blocking connective tissue growth factor. World J Orthop. 2014; 5(5): 653–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
89. van der Heijden IM, Wilbrink B, Tchetverikov I, et al.: Presence of bacterial DNA 
and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and 
other arthritides. Arthritis Rheum. 2000; 43(3): 593–8.  
PubMed Abstract | Publisher Full Text 
90. Sallusto F, Lanzavecchia A: Understanding dendritic cell and T-lymphocyte 
traffic through the analysis of chemokine receptor expression. Immunol Rev. 
2000; 177: 134–40.  
PubMed Abstract | Publisher Full Text 
91.  Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate 
in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in 
Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 
2000; 343(22): 1594–602.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
92. Ransohoff RM, Hafler DA, Lucchinetti CF: Multiple sclerosis-a quiet revolution. 
Nat Rev Neurol. 2015; 11(3): 134–42.  
PubMed Abstract | Publisher Full Text | Free Full Text 
93. Olsson T, Barcellos LF, Alfredsson L: Interactions between genetic, lifestyle and 
environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017; 13(1): 25–36. 
PubMed Abstract | Publisher Full Text 
94. Zaguia F, Saikali P, Ludwin S, et al.: Cytotoxic NKG2C+ CD4 T cells target 
oligodendrocytes in multiple sclerosis. J Immunol. 2013; 190(6): 2510–8. 
PubMed Abstract | Publisher Full Text 
Page 11 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
95. Acuto O, Michel F: CD28-mediated co-stimulation: a quantitative support for 
TCR signalling. Nat Rev Immunol. 2003; 3(12): 939–51.  
PubMed Abstract | Publisher Full Text 
96. Scotet E, Peyrat MA, Saulquin X, et al.: Frequent enrichment for CD8 T cells 
reactive against common herpes viruses in chronic inflammatory lesions: 
towards a reassessment of the physiopathological significance of T cell clonal 
expansions found in autoimmune inflammatory processes. Eur J Immunol. 
1999; 29(3): 973–85.  
PubMed Abstract | Publisher Full Text 
97. Rozenblyum EV, Allen UD, Silverman ED, et al.: Cytomegalovirus infection in 
childhood-onset systemic lupus erythematosus. Int J Clin Rheumtol. 2013; 8(1): 
137–46.  
PubMed Abstract | Free Full Text 
98. Haaheim LR, Halse AK, Kvakestad R, et al.: Serum antibodies from patients with 
primary Sjögren’s syndrome and systemic lupus erythematosus recognize 
multiple epitopes on the La(SS-B) autoantigen resembling viral protein 
sequences. Scand J Immunol. 1996; 43(1): 115–21.  
PubMed Abstract | Publisher Full Text 
99. Mak A, Kow NY: The pathology of T cells in systemic lupus erythematosus.  
J Immunol Res. 2014; 2014: 419029.  
PubMed Abstract | Publisher Full Text | Free Full Text 
100. Liossis SN, Ding XZ, Dennis GJ, et al.: Altered pattern of TCR/CD3-mediated 
protein-tyrosyl phosphorylation in T cells from patients with systemic lupus 
erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin 
Invest. 1998; 101(7): 1448–57.  
PubMed Abstract | Publisher Full Text | Free Full Text 
101. Kawakami A, Matsuoka N, Tsuboi M, et al.: CD4+ T cell-mediated cytotoxicity 
toward thyrocytes: the importance of Fas/Fas ligand interaction inducing 
apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating 
hormone. Lab Invest. 2000; 80(4): 471–84.  
PubMed Abstract | Publisher Full Text 
102. Vrbikova J, Janatkova I, Zamrazil V, et al.: Epstein-Barr virus serology in patients 
with autoimmune thyroiditis. Exp Clin Endocrinol Diabetes. 1996; 104(1): 89–92. 
PubMed Abstract | Publisher Full Text 
103.  Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al.: Stopping Tumor 
Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid 
Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic 
Multicenter, Open-Label Randomized Controlled Trial. Arthritis Rheumatol. 2016; 
68(8): 1810–7.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
104. Akbar AN, Henson SM: Are senescence and exhaustion intertwined or 
unrelated processes that compromise immunity? Nat Rev Immunol. 2011; 11(4): 
289–95.  
PubMed Abstract | Publisher Full Text 
105. Link A, Selejan S, Hewera L, et al.: Rosuvastatin induces apoptosis in 
CD4+CD28null T cells in patients with acute coronary syndromes. Clin Res 
Cardiol. 2011; 100(2): 147–58.  
PubMed Abstract | Publisher Full Text 
Page 12 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
 Open Peer Review
  Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
 Department of Immunobiology, University of Arizona College of Medicine-Tucson,Janko Nikolich-Žugich
Tucson, AZ, USA 
 No competing interests were disclosed.Competing Interests:
1
 Institute of Immunology, University Hospital Jena, Jena, Germany Thomas Kamradt
 No competing interests were disclosed.Competing Interests:
2
Page 13 of 13
F1000Research 2019, 8(F1000 Faculty Rev):327 Last updated: 25 MAR 2019
